5 Questions on Ovarian Cancer

Article

What is the effect of statin use on overall survival in elderly patients with platinum-resistant ovarian cancer? Do you know the cumulative ovarian cancer risk to age 80 years for BRCA1 and BRCA2 mutation carriers? Test your knowledge of ovarian cancer in our latest quiz.

What is the effect of statin use on overall survival in elderly patients with platinum-resistant ovarian cancer? Do you know the cumulative ovarian cancer risk to age 80 years for BRCA1 and BRCA2 mutation carriers? Test your knowledge of ovarian cancer in our latest quiz.

Question 1

Answer and Question 2 on Next Page »

Answer

C.

History of ovarian cancer in a first-degree relative

Those at the highest risk are patients with two or more first-degree relatives with ovarian cancer. According to the National Cancer Institute’s treatment guide on ovarian cancer, “approximately 20% of ovarian cancers are familial, and although most of these are linked to mutations in either the BRCA1 or BRCA2 gene, several other genes have been implicated.”

Question 2

Answer and Question 3 on Next Page »

Answer

B.

44%; 17%

The study reported that the cumulative breast cancer risk to age 80 years was 72% for BRCA1 carriers and 69% for BRCA2 carriers.

Question 3

Answer and Question 4 on Next Page »

Answer

D.

Patients who previously tolerated chemotherapy were less likely to accept its side effects

Those who previously tolerated chemotherapy were actually more likely to be accepting of its side effects, according to the study. The authors noted that overall, these findings “highlight the importance of communication with patients regarding prognosis, adverse effects, and symptom management to help negotiate the decision-making process.”

Question 4

Answer and Question 5 on Next Page »

Answer

B.

Abdominal/ gastrointestinal symptoms and physical function

According to the authors of the study: “This additional prognostic information could improve trial stratification, patient-doctor communication about prognosis, and clinical decision-making.”

Question 5

Answer on Next Page »

Answer

B.

Low-intensity statin use

“When statin treatment was categorized by lipophilicity and intensity, a significant survival benefit was limited to lipophilic statin users and those who took statins of moderate intensity,” the article states. Improved overall survival was observed in those with both serous and nonserous histologies.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
Related Content